CBP-93872 specifically suppresses G2 checkpoint through inhibition of DSB-dependent ATR activation [25, 26], and therefore is expected to enhance the effect of anticancer drugs in p53-deficient cancer cells, as the G2 checkpoint is required for survival in these cells. Here, TP53 is linked to cancer.